Advances in lipid-based platforms for RNAi therapeutics

Journal of Medicinal Chemistry

Volumn 57, Issue 4, 2014, Pages 1138-1146

  Falsini, Sara ^a,b   Ciani, Laura ^a   Ristori, Sandra ^a   Fortunato, Angelo ^b   Arcangeli, Annarosa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; SMALL INTERFERING RNA;

BIOCOMPATIBILITY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE SEQUENCE; GENE SILENCING; GENE VECTOR; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; MOLECULAR MEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ANIMALS; CAENORHABDITIS ELEGANS; GENE SILENCING; LIPIDS; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84896844960     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400791q     Document Type: Review

References (65)

1. Carpenter, A. E.; Sabatini, D. M. Systematic genome-wide screens of gene function Nat. Rev. Gen. 2004, 5, 11-22
2. Fortunato, A. Quantitative high-throughput analysis of synthetic genetic interactions in Caenorhabditis elegans by RNA interference Genomics 2009, 93, 392-396
3. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 1998, 391, 806-811
4. Wianny, F.; Zernicka-Goetz, M. Specific interference with gene function by double-stranded RNA in early mouse development Nat. Cell Biol. 2000, 2, 70-75
5. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 2001, 411, 494-498
6. Borchert, G. M.; Lanier, W.; Davidson, B. L. RNA polymerase III transcribes human microRNAs Nat. Struct. Mol. Biol. 2006, 13, 1097-1101
7. Cullen, B. R. Trascription and processing of human microRNA precursors Mol. Cell 2004, 16, 861-865
8. Zamore, P. D.; Tuschl, T.; Sharp, P. A.; Bartel, P. D. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals Cell 2000, 101, 25-33
9. Nykanen, A.; Haley, B.; Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway Cell 2001, 107, 301-321
10. Ishizu, H.; Siomi, H.; Siomi, M. C. Biology of PIWI-interacting RNAs: new insights into biogenesis and function inside and outside of germlines Genes Dev. 2012, 26 (21) 2361-2373
11. Aagaard, L.; Rossi, J. J. RNAi therapeutics: principles, prospects and challenges Adv. Drug Delivery Rev 2007, 59, 75-86
12. Davidson, B. L.; McCray, P. B., Jr. Current prospects for RNA interference-based therapies Nat. Rev. Genet. 2011, 12, 329-340
13. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol. J. 2011, 6, 1130-1146
14. Buyens, K.; De Smedt, S. C.; Braeckmans, K.; Demeester, J.; Peeters, L.; van Grunsven, L. A.; de Mollerat du Jeu, X.; Sawant, R.; Torchilin, V.; Farkasova, K.; Ogris, M.; Sanders, N. N. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design J. Controlled Release 2012, 158, 362-370
15. Stanton, M. G.; Colletti, S. L. Medicinal chemistry of siRNA delivery J. Med. Chem. 2010, 53, 7887-7901
16. Nayerossadat, N.; Maedeh, T.; Ali, P. A. Viral and nonviral delivery systems for gene delivery Adv Biomed. Res. 2012, 1, 27
17. Cullis, P. R.; Hope, M. J.; Tilcock, C. P. Lipid polymorphism and the role of lipid in membranes Chem. Phys. Lipids 1986, 40, 127-144
18. Ninham, B. W.; Lo Nostro, P. Molecular Forces and Self Assembly: In Colloid, Nano Sciences and Biology; Cambridge University Press: Cambridge, U.K., 2010.
19. Gong, J.; Chen, M.; Zheng, Y.; Wang, S.; Wang, Y. Polymeric micelles drug delivery systems in oncology J. Controlled Release 2012, 159, 312-323
20. Wang, Y.; Dubin, P. L.; Zhang, H. Interaction of DNA with cationic micelles: effects of micelle surface charge density, micelle shape, and ionic strength on complexation and DNA collapse Langmuir 2001, 17, 1670-1673
21. Ristori, S.; Ciani, L.; Candiani, G.; Battistini, C.; Frati, A.; Grillo, I.; In, M. Complexing a small interfering RNA with divalent cationic surfactants Soft Matter 2012, 8, 749-756
22. Gregoriadis, G.; Perrie, Y. Liposomes in Nanomedicine; Wiley: Hoboken, NJ, 2012.
23. Musacchio, T.; Torchilin, V. P. Recent development in lipid-based pharmaceutical nanocarriers Front. Biosci. 2011, 16, 1388-1412
24. Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 1990, 268, 235-237
25. Dos Santos, N.; Allen, C.; Doppen, A. M.; Anantha, M.; Cox, K. A. K.; Gallagher, R. C.; Karlsson, G.; Edward, K.; Kenner, G.; Samuels, L.; Webb, M. S.; Bally, M. B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding Biochim. Biophys. Acta 2007, 1768, 1367-1377
26. Yoshino, K.; Taguchi, K.; Mochizuki, M.; Nozawa, S.; Kasukawa, H. Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes Colloids Surf., A 2012, 397, 73-79
27. Allen, T. M.; Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Delivery Rev. 2013, 65, 36-48
28. Tseng, Y. C.; Mozumda, S.; Huang, L. Lipid-based systemic delivery of siRNA Adv. Drug Delivery 2009, 61, 721-731
29. Olbrich, C.; Bakowsky, U.; Lehr, C. M.; Müller, R. H.; Kneuer, C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA J. Controlled Release 2001, 77, 345-355
30. Gomes-da-Silva, L. C.; Fonseca, N. A.; Moura, V.; Pedroso de Lima, M. C.; Simões, S. J.; Moreira, N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges Acc. Chem. Res. 2012, 45, 1163-1171
31. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinner, S.; Vargeese, C.; Browman, K.; Shaffer, C. S.; Jeffs, L. B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat. Biotechnol. 2005, 23, 1002-1007
32. Leung, A. K. K.; Hafez, I. M.; Baoukina, S.; Belliveau, N. M.; Zhigaltsev, I. V.; Afshinmanesh, E.; Tieleman, D. P.; Hansen, C. L.; Hope, M. J.; Cullis, P. R. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core J. Phys. Chem. C 2012, 116, 18440-18450
33. Davidson, B. L.; McCray, P. B., Jr. Current prospects for RNA interference-based therapies Nat. Genet. 2011, 12, 329-340
34. www.clinicaltials.gov.
35. Amghesom, A.; Kaushik, A.; Kaushik, J. J.; Petros, S. T. RNA interference: a futuristic tool and its therapeutic applications Saudi J. Biol. Sci. 2012, 19, 395-403 and references therein
36. Seyhan, A. A. RNAi: a potential new class of therapeutic for human genetic disease Hum. Genet. 2011, 130, 583-605 and references therein
37. Macron, D. TransDerm's RNAi-based skin dosorder drug moves into one-patient clinical trial Gene Silencing News 2008, 6, 10
38. Zimmermann, T. S.; Lee, A. C. H.; Akinc, A.; Bramlage, B.; Bumcrot, D.; Fedoruk, M. N.; Harborth, J.; Heyes, J. A.; Jeffs, L. B.; John, M.; Judge, A. D.; Lam, K.; McClintock, K.; Nechev, L. V.; Palmer, L. R.; Racie, T.; Röhl, I.; Seiffert, S.; Shanmugam, S.; Sood, V.; Soutschek, J.; Toudjarska, I.; Wheat, A. J.; Yaworski, E.; Zedalis, W.; Koteliansky, V.; Manoharan, M.; Vornlocher, H. P.; MacLachlan, I. RNAi-mediated gene silencing in non-human primates Nature 2006, 44, 111-114
39. Akinc, A.; Zumbuehl, A.; Goldberg, M.; Leshchiner, E. S.; Busini, V.; Hossain, N.; Bacallado, S. A.; Nguyen, D. N.; Fuller, J.; Alvarez, R.; Borodovsky, A.; Borland, T.; Constien, R.; de Fougerolles, A.; Dorkin, J. R.; Jayaprakash, K. N.; Jayaraman, M.; John, M.; Koteliansky, V.; Manoharan, M.; Nechev, L.; Qin, J.; Racie, T.; Raitcheva, D.; Rajeev, K. J.; Sah, D. W. Y.; Soutschek, J.; Toudjarska, I.; Vornlocher, H. P.; Zimmermann, T. S.; Langer, R.; Anderson, D. G. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 2008, 26, 261-269
40. Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N. N.; Racie, T. S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; Gamba-Vitalo, C.; Hadwiger, P.; Jayaraman, M.; John, M.; Jayaprakash, K. N.; Maier, M.; Nechev, L.; Rajeev, K. G.; Read, T.; Röhl, I.; Soutschek, J.; Tan, P.; Wong, J.; Wang, G.; Zimmermann, T.; de Fougerolles, A.; Vornlocher, H. P.; Langer, R.; Anderson, D. G.; Manoharan, M.; Koteliansky, V.; Horton, J. D.; Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11915-11920
41. Alnylam Pharmaceuticals. Alnylam Reports Positive Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia; Business Wire News Release, April 20, 2012; www.alnylam.com.
42. Alabi, C.; Vegas, A.; Anderson, D. Attacking the genome: emerging siRNA nanocarriers from concenpt to clinic Curr. Opin. Pharmacol. 2012, 12, 427-433
43. Jayaraman, M.; Ansell, S. T.; Mui, B. L.; Tam, Y. K.; Chem, J.; Du, X.; Butler, D.; Eltepu, L.; Matsuda, S.; Narayanannair, J. K.; Rajeev, K. G.; Hafez, I. M.; Akinc, A.; Maier, M. A.; Tracy, M. A.; Cullis, P. R.; Madden, T. D.; Manoharan, M.; Hope, M. J. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo Angew. Chem., Int. Ed. 2012, 51, 8529-8533
44. Alnylam Pharmaceutics. Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). Business Wire News Release, June 30, 2013; www.alnylam.com.
45. Alnylam Pharmaceutics. Alnylam Reports Positive Clinical Results for ANL-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. Business Wire News Release, 2013; www.alnylam.com.
46. Alnylam Pharmaceutics. Alnylam Files Clinical Trial Application to Initiate a Phase I Study for TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). Business Wire News Release, 2012; www.alnylam.com.
47. Maier, M. A.; Jayaraman, M.; Matsuda, S.; Liu, J.; Barros, S.; Querbes, W.; Tam, Y. K.; Ansell, S. K.; Kumar, V.; Qin, J.; Zhang, X.; Wang, Q.; Panesar, S.; Hutabarat, R.; Carioto, M.; Hettinger, J.; Kandasamy, P.; Butler, D.; Rajeev, K. G.; Pang, B.; Charisse, K.; Fitzgerald, K.; Mui, B. L.; Du, X.; Cullis, P.; Madden, T. D.; Hope, M. J.; Manoharan, M.; Akinc, A. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics Mol. Ther. 2013, 21, 1570-1578
48. Blight, K. J.; Kolykhalov, A. A.; Rice, C. M. Efficient initiation of HCV RNA replication in cell culture Science 2000, 290, 1972-1974
49. Song, E.; Lee, S. K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis Nat. Med. 2003, 9, 347-351
50. Bonamassa, B.; Hai, L.; Liu, D. Hydrodynamic gene delivery and its applications in pharmaceutical research Pharm. Res. 2011, 28, 694-701
51. Palliser, D.; Chowdhury, D.; Wang, Q. Y.; Lee, S. J.; Bronson, R. T.; Knipe, D. M.; Lieberman, J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 2006, 439, 89-94
52. Wu, Y.; Navarro, F.; Lal, A.; Basar, E.; Pandey, R. K.; Manoharan, M.; Feng, Y.; Lee, S. J.; Lieberman, J.; Palliser, D. Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene Cell Host Microbe 2009, 5, 84-94
53. Geisbert, T. W.; Lee, A. C. H.; Robbins, M.; Geisbert, J. B.; Honko, A. N.; Sood, V.; Johnson, J. C.; de Jong, S.; Tavakoli, I.; Judge, A.; Hensley, L. E.; MacLachlan, I. Postexposure protection of non-human primates against a lethal ebola virus challenge with RNA interference: a proof-of-concept study Lancet 2010, 375, 1896-1905
54. Tekmira Pharmaceuticals Corporation. Products. http://www.tekmirapharm. com/Programs/Products.asp#ebola.
55. D'Amico, M.; Gasparoli, L.; Arcangeli, A. Potassium channels: novel emerging biomarkers and targets for therapy in cancer Recent Pat. Anti-Cancer Drug Discovery 2013, 8, 53-65
56. Navarro, G.; Sawant, R. R.; Biswas, S.; Essex, S.; Tros de Ilarduya, C.; Torchilin, V. P. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breat cancer cells Nanomedicine 2012, 7, 65-78
57. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and argumentation of the effect Adv. Drug Delivery Rev. 2011, 63, 136-151
58. Lander, C. N.; Chavez-Reyes, A.; Bucana, C.; Schmendt, R.; Deavers, M. T.; Lopez-Berestein, G.; Sood, A. K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res. 2005, 65, 6910-6918
59. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Fisch, G.; Dames, S.; Löffler, K.; Fechtner, M.; Arnold, W.; Giese, K.; Klippel, A.; Kaufmann, J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther. 2006, 13, 1222-1234
60. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Durieux, B.; Löffler, K.; Fechtner, M.; Röhl, T.; Fisch, G.; Dames, S.; Arnold, W.; Giese, K.; Klippel, A.; Kaufmann, J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy Gene Ther. 2006, 13, 1360-1370
61. Judge, A. D.; Robbins, M.; Tavakoli, I.; Levi, J.; Hu, L.; Fronda, A.; Ambegia, E.; McClintock, K.; MacLachlan, I. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice J. Clin. Invest. 2009, 119, 661-673
62. Tabernero, J.; Shapiro, G. I.; Lorusso, P. M.; Cervantes, A.; Schwartz, G. K.; Weiss, G. J.; Paz-Ares, L.; Cho, D. C.; Infante, J. R.; Alsina, M.; Mrinal, M.; Gounder, M. M.; Falzone, R.; Harrop, J.; White, A. C. S.; Toudjarska, I.; Bumcrot, D.; Meyers, R. E.; Hinkle, G.; Svrzikapa, N.; Renta, M.; Hutabarat, R. M.; Clausen, V. A.; Cehelsky, J.; Nochur, S. V.; Gamba-Vitalo, C.; Vaishnaw, A. K.; Sah, D. W. Y.; Gollob, J. A.; Burris, H. A., III. First-in-man trial of a RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement Cancer Discovery 2013, 3, 406-417
63. Koldehoff, M.; Steckel, N. K.; Beelen, D. W.; Elmaagacli, A. H. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia Clin. Exp. Med. 2007, 7, 47-55
64. Rana, S.; Maples, P. B.; Senzer, N.; Nemunaitis, J. Stathmin 1: a novel therapeutic target for anticancer activity Expert Rev. Anticancer Ther. 2008, 8, 1461-1470
65. Templeton, N. S.; Senzer, N. Optimization of non-viral gene therapeutics using bilamellar invaginated vesicles. J. Genet. Syndr. Gene Ther. 2011, December 17) 002, DOI: 10.4172/2157-7412.S5-002.